Abstract
Purpose The novel coronavirus disease 2019 (COVID-19) worldwide pandemic has placed a significant burden on hospitals and healthcare providers. The immune response to this disease is thought to lead to a cytokine storm, which contributes to the severity of illness. There is an urgent need to confirm whether the use of tocilizumab provides a benefit in individuals with COVID-19.
Methods A single-center propensity-score matched cohort study, including all consecutive COVID-19 patients, admitted to the medical center who were either discharged from the medical center or expired between March 1, 2020, and May 5, 2020, was performed. Patients were stratified according to the receipt of tocilizumab for cytokine storm and matched to controls using propensity scores. The primary outcome was in-hospital mortality.
Results A total of 132 patients were included in the matched dataset (tocilizumab=66; no tocilizumab=66). Approximately 73% of the patients were male. Hypertension (55%), diabetes mellitus (31%), and chronic pulmonary disease (15%) were the most common comorbidities present. There were 18 deaths (27.3%) in the tocilizumab group and 18 deaths (27.3%) in the no tocilizumab group (odds ratio, 1.0; 95% confidence interval, 0.465 – 2.151; p=1.00). Advanced age, history of myocardial infarction, dementia, chronic pulmonary disease, heart failure, and malignancy were significantly more common in patients who died.
Conclusion The current analysis does not support the use of tocilizumab for the management of cytokine storm in patients with COVID-19. Use of this therapeutic agent should be limited to the context of a clinical trial until more evidence is available.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
There was no funding received for the completion of this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Robert Wood Johnson University Hospital Somerset IRB gave expedited review and approval of our study. Waiver of informed consent and HIPPA authorization was obtained as this was a non-interventional study of routinely collected data for secondary research purposes.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Declarations
Funding: There was no funding received for the completion of this study.
Conflicts of interest/Competing interests: The authors declare that they have no conflicts of interest.
Availability of data and material: Available upon request.
Code availability: Not applicable.
Authors’ contributions: All authors had full access to the study data and take responsibility for the integrity of the data and the data analysis. AT, OD, LB, and RN were responsible for the study concept and design. AT, OD and LB were responsible for data acquisition and adjudication. AT and LB drafted the initial manuscript. LB performed the statistical analysis. All authors reviewed and provided input at each step.
Data Availability
The data that support the findings of this study are available upon request from the corresponding author, LB. The data are not publicly available due to their containing information that could compromise the privacy of research participants.
